Quarterly ResultMay 8, 2026, 04:18 PM
Caris Life Sciences Q1 Revenue +78.8% to $216.2M; Net Loss Nears Break-Even
AI Summary
Caris Life Sciences reported a significant improvement in its financial performance for Q1 2026. Total revenue surged by 78.8% to $216.2 million, primarily driven by an 84.8% increase in molecular profiling services. The company dramatically reduced its net loss from $102.6 million in Q1 2025 to just $0.5 million in Q1 2026, with net loss per share improving to $0.00. Operating cash flow also turned positive, reaching $32.9 million.
Key Highlights
- Total revenue increased 78.8% to $216.2 million for Q1 2026.
- Molecular profiling services revenue grew 84.8% to $210.8 million.
- Net loss significantly reduced to $0.5 million from $102.6 million year-over-year.
- Net loss per share improved to $0.00 from $(3.57) in Q1 2025.
- Net cash provided by operating activities was $32.9 million, up from a $31.3 million use.
- Cash, cash equivalents, and restricted cash totaled $821.1 million as of March 31, 2026.
Price Impact
More from CAI